• Citer

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

par Kanti, Varvara;Piraccini, Bianca Maria;Nast, Alexander;Blume-Peytavi, Ulrike;Messenger, Andrew;Dobos, Gabor;Reygagne, Pascal;Finner, Andreas;Blumeyer, Anja;Trakatelli, Myrto Georgia ;Tosti, Antonella;Del Marmol, Véronique
Référence JEADV. Journal of the European Academy of Dermatology and Venereology, 32, 1, page (11-22)
Publication Publié, 2018-01

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.